The regenerative medicine industry is a high-value, fast-growth market. With two CAR-T approvals, as well as the first gene therapy and digital pill approvals in the United States, we have had a lot of FDA “firsts.” The market gathered momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta), further “snowballing” the effect. [Read more…]
BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies
STOCKHOLM, May 16, 2018 — BioLamina and collaborators have partnered with Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, allowing Novo Nordisk to develop novel stem cell based therapies based on Biolaminins, human recombinant laminin cell culture matrices, developed and produced by BioLamina. [Read more…]
Market Players Developing iPS Cell Therapies
While a number of companies have dabbled in this space, the following players are leaders in the development of iPS cell therapies: Cellular Dynamics International (a Fujifilm Company), Cynata Therapeutics, RIKEN, and Astellas (previously Ocata Therapeutics).
iPS Cell Therapy Market Players
In this article:
- Cellular Dynamics International, Owned by FujiFilm
- Cynata Therapeutics
- RIKEN
- Astellas, Previously Ocata Therapeutics
Leading iPS Cell Therapy Companies
The four companies and organizations below are major innovators of iPSC therapeutics.
[Read more…]
Hemostemix Announces First Patient Treated in Phase II Clinical Trial
CALGARY, Alberta, May 03, 2018 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) announces that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”). The first patient was treated at the Vancouver Coastal Health Research Institute (“VCHRI”), a world leader in translational health research for new therapies, led by the principal investigator, Dr. York N. Hsiang, MB ChB MHSc FRCSC. [Read more…]
Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration Developed at IU School of Medicine
Company is developing adult stem cell-based therapies for patients with incurable vascular conditions
INDIANAPOLIS, May 1, 2018 — Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. [Read more…]
- « Previous Page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- …
- 202
- Next Page »